RANBAXY

TO5 Rec'd PCT/PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Kumar et al.

Group Art Unit:

TECH CENTER 1600/2900

Serial No.:

Applicants:

10/009,230

Filing Date: May 25, 2000

Title: AMORPHOUS FORM OF FEXOFENADINE HYDROCHLORIDE

Certificate of Facsimile Transmission

I certify that this document, consisting of 3 pages, is being facsimile transmitted to the U.S. Patent and Trademark Office (Fax. No. 703-746-9195) on September 9, 2002.

Ausan Dolci
Susan Dolci

Commissioner for Patents Office of Initial Patent Examination Filing Receipt Corrections Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

Dear Sir:

Attached is a copy of the updated filing receipt mailed on July 18, 2002. Please make the following corrections on the same:

In the Applicant(s):

Inventor Naresh Kumar's town is misspelled; it should read Haryana.

The correction is shown on the attached filing receipt. Applicants request a new updated filing receipt be issued reflecting the above change.

Respectfully submitted,

Javadeep R. Deshmukh, Esq.

Reg. No. 34,507

Dated: September 9, 2002

Ranbaxy Laboratories Limited 600 College Road East, Suite 2100 Princeton, New Jersey 08540 T lephone: (609) 720-5608

Facsimile: (609) 514-9779

SEP. 9.2002 2:25PM RANBAXY





United States Patent and Trademark Office

TECH CENTER 1920/22009.2002

Commissioner for Patents United States Patent and Trademark Office Washington, D.C. 20231 www.uspio.gov

APPLICATION NUMBER FILING DATE GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS IND CLAIMS 10/009.230 05/17/2002 1614 970 RLL-159US 4 13 2

CONFIRMATION NO. 5863

Jayadeep R Deshmukh Ranbaxy Laboratories Limited Suite 2100 600 College Road East Princeton, NJ 08540 Date Mailed; 07/18/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when Inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filling Receipt, please write to the Office of Initial Patent Examination's Filling Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filling Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filling Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filling Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Naresh Kumar, Gurgaon Haryama INDIA; Chandras Has Khanduri, Gurgaon Haryana, INDIA;

Mukesh Sharma, Gurgaon Haryana, INDIA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/IB00/00708 05/25/2000

Foreign Applications

INDIA 776/DEL/99 05/25/1999

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

Title

Amorphous form of fexofenadine hydrochloride

Preliminary Class



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(S) filed under 37 CFR 1,53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).